Women were less than half of the people tested for almost all of these common medicines.

Heartburn & acid reflux

pantoprazole

One of the most-used stomach medicines, yet only about 1 in 4 people in its studies were women.

  • 26.8%

    of the people in the studies were women

  • 68%

    of studies did not allow pregnant women

  • 2%

    looked at results for women separately

Was someone like me tested?

Choose the group that fits you.

Not one of these studies reported results separately for any of the groups below.

Not studied

Pregnant women

68% of studies would not let pregnant women join, and we found no study that tested this medicine in pregnancy.

What do we know?

What the FDA drug label says

Studies that followed women who took it while pregnant found no link to birth defects. Animal studies showed bone changes in babies, so the label still warns of possible harm.

Good to know

Long-term use of this type of medicine is linked to weaker bones and fractures. Women past menopause already have a higher fracture risk.

What women report more

Compared with men taking the same medicine.

  • 2.6Γ—Physical symptoms with no clear cause
  • 2.2Γ—Eye problems
  • 2.1Γ—Ear problems
  • 2.1Γ—Changes to the front of the eye

How many times more often women reported each problem than men taking the same medicine, based on reports to the FDA. This is a warning sign, not proof the medicine caused it.

Make it about you

Check it against your medicines

Check pantoprazole against the medicines, pregnancy and birth control in your profile.

Join to check

Women's experiences

Join or sign in to share, like or save. You'll fill in a short health profile so your story has context and we can check your medicines.

No one has shared yet. Your story could help the next woman.

All the details

Every number behind this page.

Who was in the studies

36,659 people in 41 studies

9,815 womenmiddle line = equal numbers26,844 men

Race

  • White54.9%
  • Hispanic / Latina16.8%
  • Asian15%
  • Other1.8%
  • Black / African American1%

Studies didn't say how many of the women were Black, Asian or another race β€” only totals for everyone.

Hispanic or Latina
5.7%
Age 65 or older
20.6%
Studies with men only
1
Studies with women only
0
Rules that kept women out

Share of studies with each rule.

  • 68%

    No pregnant women

    Women who were pregnant could not join.

    See the exact rule
    β€œβ€¦ion less than or equal to 1 year prior to informed consent) who: are nursing or pregnant, or are of child bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughou…” NCT01493557
  • 37%

    Age limit under 65

    Older women were turned away, even though they often take this medicine.

    See the exact rule
    β€œMaximum age: 11 Months.” NCT00365300
  • 29%

    No breastfeeding moms

    Women who were breastfeeding could not join.

    See the exact rule
    β€œPregnant or lactating women” NCT02159976
  • 20%

    No diabetes

    Women with diabetes were turned away.

    See the exact rule
    β€œβ€¦alcohol consumption (past 2 years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular, disease, tuberculosis, epilepsy, asthma (past 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.” NCT00835588
  • 17%

    Weight limit (BMI)

    Women with a higher (or lower) body weight were turned away.

    See the exact rule
    β€œAll subjects selected for this study will be non-smokers at least 18 years of age. Subjects will have a BMI(Body Mass Index) of 30 or less.” NCT00835588
  • 17%

    No heart disease

    Women with heart disease, heart rhythm problems or a past heart attack were turned away.

    See the exact rule
    β€œSevere heart failure with known ejection fraction \<30% or New York Heart Association (NYHA) class III or IV symptoms” NCT01776424
What nobody checked

Share of studies that recorded each thing.

  • 2%
    Results shown separately for women
  • 0%
    Whether anyone was pregnant
  • 0%
    Whether women were past menopause
  • 17%
    Body weight (BMI)
  • 10%
    Hispanic / Latina or not
  • 27%
    Race
All 41 studies

Study titles and rules are shown in their original English.

StudyPhasepeople% women
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
NCT01776424
327,39522%
Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)
NCT00562094
β€”8,61648%
Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease
NCT00829738
β€”4,18847.8%
Stress Ulcer Prophylaxis in the Intensive Care Unit
NCT02467621
43,29136%
Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
NCT00561730
β€”1,99546.4%
A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
NCT01493557
41,06732.4%
Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
NCT00830115
β€”1,04546%
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection
NCT02359435
β€”44047%
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
NCT02159976
β€”39043.6%
Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy
NCT02547038
β€”35252.3%
Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication
NCT02541864
β€”33047.6%
Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
NCT01769365
430743%
Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients
NCT02432456
415031.3%
13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
NCT00825630
412366.7%
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
NCT00365300
310635.8%
Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
NCT01477320
β€”10243.1%
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
NCT02551744
β€”10122.8%
Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions
NCT00835588
110033%
Structured Non-operative Treatment of Knee Osteoarthritis
NCT01535001
β€”10051%
Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor
NCT06154226
29839.8%
Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole
NCT01281501
48778.2%
Effect of Obesity on Proton Pump Inhibitors
NCT04248335
47653.9%
Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD
NCT00259012
36741.8%
Comparison of Pantoprazole and Ranitidine in Dyspepsia
NCT01737840
46660.6%
Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study
NCT01887743
16561.5%
Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)
NCT00300755
36038.3%
Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD
NCT00362609
35930.5%
Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)
NCT00868296
35844.8%
Aspirin in Young Psychotic Patients
NCT02685748
2/35742.1%
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
NCT03094416
44776.6%
PK Study With Pantoprazole in Obese Children and Adolescents
NCT02186652
14156.1%
Study Evaluating Pantoprazole in Children With GERD
NCT00141817
34139%
Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole
NCT00668902
β€”2560%
PPI and Clopidogrel Response
NCT01170533
1250%
Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS
NCT01801280
42040%
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
NCT00938366
11844.4%
Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608
NCT01703858
1150%
Pantoprazole on Insulin Secretion in Diabetes
NCT01541735
2/31478.6%
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
NCT01848457
21361.5%
Incretin Effect and Use After Clinical Islet Transplantation
NCT00768651
2812.5%